Volume 10, Number 5—May 2004
Research
Multidrug-resistant Tuberculosis in Central Asia
Helen Suzanne Cox*
, Juan Daniel Orozco*, Roy Male*, Sabine Ruesch-Gerdes†, Dennis Falzon*, Ian Small*, Darebay Doshetov‡, Yared Kebede§, and Mohammed Aziz¶
, Juan Daniel Orozco*, Roy Male*, Sabine Ruesch-Gerdes†, Dennis Falzon*, Ian Small*, Darebay Doshetov‡, Yared Kebede§, and Mohammed Aziz¶Table 1
Key characteristics of the two regions and countries included in the surveya
| Uzbekistan | Turkmenistan | |
|---|---|---|
| Population (6) | 25,256,000 | 4,834,000 |
| GDP per capita (6) | U.S.$ 2,333 | U.S.$ 5,269 |
| Health expenditure per capita (6) | U.S.$ 86 | U.S.$ 286 |
| Estimated TB incidence rate (all cases) (7) | 92/100,000/y | 84/100,000/y |
| Estimated smear-positive case detection (7) | 44% | 68% |
| Karakalpakstan | Dashoguz | |
| Population (2001 estimated)b | 1,549,761 | 1,041,372 |
| DOTS implementation | 1998 (pilot districts)–2003 (full coverage) | 2000 (pilot districts)–2002 (full coverage) |
| DOTS case notification rate (all cases) | 482/100,000/y | 213/100,000/y |
| DOTS case notification rate (smear- positive cases) | 192/100,000/y | 89/100,000/y |
| % of smear-positive cases previously treated (2002) | 55 | 53 |
| Success rate (new smear-positive cases registered in 2001) | 68% | 82% |
aGDP, gross domestic product; TB, tuberculosis; DOTS, directly observed treatment strategy.
bSource: ministries of health in each region.
